ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Samsung Biologics inks supply deal with AstraZeneca

by Rick Mullin
September 26, 2020 | APPEARED IN VOLUME 98, ISSUE 37

 

Samsung Biologics has signed an agreement to provide commercial manufacturing of AstraZeneca biologic drugs at its facility in Incheon, South Korea. The long-term contract, valued at $331 million, could be increased to $546 million. Earlier this year, Samsung announced a $362 million deal with Vir Biotechnology in which it will provide commercial production of a monoclonal antibody against the novel coronavirus.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment